Acumen Pharmaceuticals (ABOS) Non-Current Debt (2023 - 2026)

Acumen Pharmaceuticals has disclosed Non-Current Debt across 4 years of filings, most recently posting $11.9 million for Q2 2026.

• In Q2 2026, Non-Current Debt fell 60.19% year-over-year to $11.9 million; the TTM figure through Jun 2026 stood at $11.9 million (down 60.19% YoY), while the FY2025 annual figure was $22.4 million, down 23.87% from the prior year.
• Non-Current Debt came in at $11.9 million for Q2 2026 at Acumen Pharmaceuticals, down from $16.9 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $30.2 million in Q1 2024 to a low of $11.9 million in Q2 2026.
• Average Non-Current Debt over 4 years is $26.0 million, with a median of $29.4 million recorded in 2024.
• Year-over-year, Non-Current Debt rose 1.71% in 2025 and slumped 60.19% in 2026.
• Over 4 years, Non-Current Debt stood at $29.9 million in 2023, then declined by 1.6% to $29.4 million in 2024, then retreated by 23.87% to $22.4 million in 2025, then tumbled by 46.88% to $11.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $11.9 million in Q2 2026, $16.9 million in Q1 2026, and $22.4 million in Q4 2025.